Scientific Advisory Board

MILabs is proud to have established an international Scientific Advisory Board with leading experts in Molecular Imaging and Nuclear Medicine.

Prof. Joseph Peter Ell, MD.

Peter Ell is the Director of the Institute of Nuclear Medicine, University College London. For many years he was the editor of the highly ranked European Journal of Nuclear Medicine. He is the author of numerous papers in outstanding journals like The Lancet, The Journal of Nuclear Medicine, and The New England Journal of Medicine. For many years, Peter Ell has served as the President of the European Society of Nuclear Medicine.

Prof. Sanjiv Gambhir

Sanjiv Gambhir is the Director of the Molecular Imaging Program at Stanford, Division Chief of the Nuclear Medicine Program, and Professor of Radiology & Bioengineering at Stanford. He is generally regarded as one of the leading scientists in Molecular Imaging and he was a true pioneer in gene-expression imaging methods with Nuclear Imaging Methods. He has published many papers in Nature Medicine, Science and P.N.A.S.

Prof. Max A. Viergever

Max Viergever is Director of the Research School for Biomedical Image Sciences of the University Medical Center Utrecht, The Netherlands. Max has a mathematics background and is the Editor-in-Chief of the highest ranking journal for image processing, mathematics and physics applied to Medical Imaging: IEEE Transactions in Medical Imaging.

Prof. Rudi A. Dierckx

Rudi Dierckx is Professor of Nuclear Medicine at the University Medical Center of Groningen (UMCG) and Department Head of Nuclear Medicine and Molecular Imaging. His research is focused on the development of new nuclear imaging methods and radiopharmaceuticals, and the evaluation of existing procedures. Rudi Dierckx is also a trained Neuropsychiatrist and has a Master of Business Administration.

Prof. Otto C. Boerman

Otto C. Boerman (Lochem, 1959) studied Chemistry at the University of Nijmegen in The Netherlands. From 1985 until 1990, he was a junior investigator at the Department of Cell Biology at the University of Nijmegen, where he wrote his thesis, entitled “Development and Application of Monoclonal Antibodies Against Ovarian Carcinoma-Associated Antigens.”
As a fellow of the Dutch Cancer Society he worked at the Center for Molecular Medicine and Immunology in Newark, NJ (1990-1991) on targeting cancer with radiolabeled monoclonal antibodies. Subsequently, he worked at the Biological Response Modifiers Program of the National Institutes of Health in Frederick, MD (1991-1992) on the in vivo effects of IL-7. When he returned to The Netherlands in 1992, he started his preclinical research group at the Department of Nuclear Medicine of the Radboud University Nijmegen Medical Center. In his group preclinical research focuses on radionuclide imaging and therapy with radiolabeled peptides and antibodies. Prof.dr. Boerman is a member of the editorial board of The Journal of Nuclear Medicine and The European Journal of Nuclear Medicine and Molecular Imaging. He is a (co-)author of more than 275 peer reviewed scientific publications.



Home Corporate Profile Mission Management Team Scientific Advisory Board Career Preclinical Imaging U-SPECT II U-CT U-SPECT/CT Product brochures Collimators FAQ Accessories Images News Links Representations Contact
Latest News Vacancy Business Director North and South-America MILabs wins two contracts for the newly launched U-SPECT/CT. MILabs launches U-SPECT/CT at SNM Toronto Interview in Next Generation Pharmaceutical U-Overlay™ allows fast field of view selection Archive	Home > Corporate > Scientific Advisory Board Scientific Advisory Board MILabs is proud to have established an international Scientific Advisory Board with leading experts in Molecular Imaging and Nuclear Medicine. Prof. Joseph Peter Ell, MD. Peter Ell is the Director of the Institute of Nuclear Medicine, University College London. For many years he was the editor of the highly ranked European Journal of Nuclear Medicine. He is the author of numerous papers in outstanding journals like The Lancet, The Journal of Nuclear Medicine, and The New England Journal of Medicine. For many years, Peter Ell has served as the President of the European Society of Nuclear Medicine. Prof. Sanjiv Gambhir Sanjiv Gambhir is the Director of the Molecular Imaging Program at Stanford, Division Chief of the Nuclear Medicine Program, and Professor of Radiology & Bioengineering at Stanford. He is generally regarded as one of the leading scientists in Molecular Imaging and he was a true pioneer in gene-expression imaging methods with Nuclear Imaging Methods. He has published many papers in Nature Medicine, Science and P.N.A.S. Prof. Max A. Viergever Max Viergever is Director of the Research School for Biomedical Image Sciences of the University Medical Center Utrecht, The Netherlands. Max has a mathematics background and is the Editor-in-Chief of the highest ranking journal for image processing, mathematics and physics applied to Medical Imaging: IEEE Transactions in Medical Imaging. Prof. Rudi A. Dierckx Rudi Dierckx is Professor of Nuclear Medicine at the University Medical Center of Groningen (UMCG) and Department Head of Nuclear Medicine and Molecular Imaging. His research is focused on the development of new nuclear imaging methods and radiopharmaceuticals, and the evaluation of existing procedures. Rudi Dierckx is also a trained Neuropsychiatrist and has a Master of Business Administration. Prof. Otto C. Boerman Otto C. Boerman (Lochem, 1959) studied Chemistry at the University of Nijmegen in The Netherlands. From 1985 until 1990, he was a junior investigator at the Department of Cell Biology at the University of Nijmegen, where he wrote his thesis, entitled “Development and Application of Monoclonal Antibodies Against Ovarian Carcinoma-Associated Antigens.” As a fellow of the Dutch Cancer Society he worked at the Center for Molecular Medicine and Immunology in Newark, NJ (1990-1991) on targeting cancer with radiolabeled monoclonal antibodies. Subsequently, he worked at the Biological Response Modifiers Program of the National Institutes of Health in Frederick, MD (1991-1992) on the in vivo effects of IL-7. When he returned to The Netherlands in 1992, he started his preclinical research group at the Department of Nuclear Medicine of the Radboud University Nijmegen Medical Center. In his group preclinical research focuses on radionuclide imaging and therapy with radiolabeled peptides and antibodies. Prof.dr. Boerman is a member of the editorial board of The Journal of Nuclear Medicine and The European Journal of Nuclear Medicine and Molecular Imaging. He is a (co-)author of more than 275 peer reviewed scientific publications.

© 2009 MILabs B.V. \| Disclaimer \| Webdesign: DVB MEDIA B.V.